Remed Co

Remed Co FCF per Share

The Free Cash Flow per Share of Remed Co (302550.KQ) as of Nov 19, 2026 is 50.05 KRW. In the previous year, Free Cash Flow per Share was 20.75 KRW — a change of 141.22% (higher).

FCF per Share

50.05KRW

YoY

141.22%

Last updated:

Free Cash Flow per Share of Remed Co is 2025 50.05 KRW. Free Cash Flow per Share of Remed Co was 2024 20.75 KRW. It decreases by 141.22% higher compared to the previous year.

The Remed Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-1,030.49 KRW
Jan 1, 2019
208.25 KRW
Jan 1, 2020
313.85 KRW
Jan 1, 2021
-1,365.75 KRW
Jan 1, 2022
72.06 KRW
Jan 1, 2023
85.02 KRW
Jan 1, 2024
20.75 KRW
Jan 1, 2025
50.05 KRW
The Remed Co FCF per Share history
YEARFCF per ShareYoY
50.05KRW+141.22%
20.75KRW-75.60%
85.02KRW+17.99%
72.06KRW-105.28%
-1,365.75KRW-535.17%
313.85KRW+50.70%
208.25KRW-120.21%
-1,030.49KRW+197.28%
-346.64KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Free Cash Flow per Share of Remed Co is 50.05 KRW in 2025.

Free Cash Flow per Share of Remed Co changed from 20.75 KRW to 50.05 KRW, representing a 141.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Remed Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Remed Co

All Key Metrics — Remed Co